PMAC President Judy Erola acknowledged the problem when she testified last fall that "some have said that the industry has never invested this kind of money in the past so why would it be expected to do so in the future? We have not done so precisely because we were never sure that our investments would be protected for a defined period of time."
A 1969 change in the patent act allowed generic drug manufacturers to produce copies of patented products once they had appeared on the market under what was called "compulsory licensing." This effectively reduced the patent protection offered the drug's originator, which was 17 years from the date of filing.
BY TED AGRES Washington - A new law gives a civilian agency the authority to set standards on access to unclassified data, including scientific and technical information. The law ends a long debate over how to protect ...
